Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.9M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
18.4M
-
Shares change
-
-202K
-
Total reported value, excl. options
-
$139M
-
Value change
-
-$1.13M
-
Put/Call ratio
-
0
-
Number of buys
-
47
-
Number of sells
-
-58
-
Price
-
$7.56
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2025
124 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q2 2025.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.4M shares
of 27.9M outstanding shares and own 66.12% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (2.12M shares), Krensavage Asset Management, LLC (2.11M shares), VANGUARD GROUP INC (1.98M shares), BlackRock, Inc. (1.85M shares), MILLENNIUM MANAGEMENT LLC (1.46M shares), ACADIAN ASSET MANAGEMENT LLC (867K shares), MARSHALL WACE, LLP (857K shares), Stonepine Capital Management, LLC (604K shares), JANUS HENDERSON GROUP PLC (524K shares), and GEODE CAPITAL MANAGEMENT, LLC (486K shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.